Locoregional therapies combined with immune checkpoint inhibitors for liver metastases
Cancer Cell International · 31.08.2024 · 24 (1)
DOI: 10.1186/s12935-024-03484-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell International, online erschienen am 31.08.2024. Verfasst von Xing-Chen Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Cancer Center, West China Hospital of Sichuan University, 37 Guoxue Xiang Street, Chengdu, 610041, Sichuan Province, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University, Sichuan Science and Technology Department Key Research and Development Project.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have achieved remarkable success in clinical research and practice. Notably, liver metastasis is not sensitive to ICIs. Liver locoregional therapies can cause irreversible damage to tumor cells and release tumor antigens, thereby providing a rationale for immunotherapy treatments in liver metastasis. The combination therapy of ICIs with locoregional therapies is a promising option for patients with liver metastasis. Preclinical studies have demonstrated that combining ICIs with locoregional therapies produces a significantly synergistic anti-tumor effect. However, the current evidence for the efficacy of ICIs combined with locoregional therapies remains insufficient. Therefore, we review the literature on the mechanisms of locoregional therapies in treating liver metastasis and the clinical research progress of their combination with ICIs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Colorectal Cancer Center, West China Hospital of Sichuan University, 37 Guoxue Xiang Street, Chengdu, 610041, Sichuan Province, China.
- Department of Abdominal Cancer, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
- Department of Colorectal Cancer Center, West China Hospital of Sichuan University, 37 Guoxue Xiang Street, Chengdu, 610041, Sichuan Province, China. qiumeng_333@163.com.
Förderung
- 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
- Sichuan Science and Technology Department Key Research and Development Project
Zitieren
APA
Zhang, X. C., Zhou, Y. W., Wei, G. X., Luo, Y. Q., & Qiu, M. (2024). Locoregional therapies combined with immune checkpoint inhibitors for liver metastases. Cancer Cell International, 24(1). https://doi.org/10.1186/s12935-024-03484-1
Vancouver
Zhang XC, Zhou YW, Wei GX, Luo YQ, Qiu M. Locoregional therapies combined with immune checkpoint inhibitors for liver metastases. Cancer Cell International. 2024;24(1). doi:10.1186/s12935-024-03484-1
BibTeX
@article{Zhang2024,
author = {Zhang, Xing-Chen and Zhou, Yu-Wen and Wei, Gui-Xia and Luo, Yi-Qiao and Qiu, Meng},
title = {Locoregional therapies combined with immune checkpoint inhibitors for liver metastases},
journal = {Cancer Cell International},
year = {2024},
volume = {24},
number = {1},
doi = {10.1186/s12935-024-03484-1}
}
EUVIMED